Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 10/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.53 |
| ▸ | GPBAR1 | Q8TDU6 | 2/20 | 0.47 |
| ▸ | AVPR1A | P37288 | 5/20 | 0.45 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4900069 | 0.83 | SLC22A12 (0.63) | SLC22A12CYP2C9ABCG2AVPR1AAVPR2 | |
| SCHEMBL30379071 | 0.82 | HTT (0.57) | GPBAR1AVPR1AAVPR2ALDH1A1BRD4 | |
| SCHEMBL26088243 | 0.82 | HTT (0.57) | GPBAR1AVPR1AAVPR2ALDH1A1BRD4 | |
| SCHEMBL4898058 | 0.81 | AVPR1A (0.44) | SLC22A12GPBAR1AVPR1AAVPR2ALDH1A1 | |
| SCHEMBL4900343 | 0.81 | BRD4 (0.64) | SLC22A12CYP2C9ABCG2ALDH1A1LMNA | |
| SCHEMBL4892229 | 0.77 | SLC22A12 (0.56) | SLC22A12CYP2C9ABCG2GPBAR1AVPR1A | |
| SCHEMBL4902320 | 0.77 | SLC22A12 (0.77) | SLC22A12CYP2C9ABCG2ALDH1A1 | |
| SCHEMBL26933868 | 0.77 | AVPR1A (0.51) | AVPR1AAVPR2ALDH1A1BRD4 | |
| SCHEMBL30673873 | 0.77 | AVPR1A (0.51) | AVPR1AAVPR2ALDH1A1BRD4 | |
| SCHEMBL30673867 | 0.76 | HTT (0.62) | AVPR1AAVPR2ALDH1A1BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080064871-A1 | Production Method of Nitrogen-Containing Fused Ring Compounds | JAPAN TOBACCO INC. (JP) | 2008-03-13 | — | — | US | claimed |
| EP-1820515-A1 | NITROGEN-CONTAINING FUSED RING COMPOUND AND USE THEREOF | Japan Tobacco, Inc. (JP) | 2007-08-22 | — | — | EP | claimed |
| US-20070010670-A1 | Nitrogen-containing fused ring compounds and use thereof | JAPAN TOBACCO INC. (JP) | 2007-01-11 | — | — | US | claimed |
| US-20080305169-A1 | Pharmaceutical Compositions Comprising Nitrogen-Containing Fused Ring Coumpounds | JAPAN TOBACCO INC. (JP) | 2008-12-11 | — | — | US | disclosed |
| US-20080305169-A1 | Pharmaceutical Compositions Comprising Nitrogen-Containing Fused Ring Coumpounds | JAPAN TOBACCO INC. (JP) | 2008-12-11 | — | — | US | disclosed |
| US-20080305169-A1 | Pharmaceutical Compositions Comprising Nitrogen-Containing Fused Ring Coumpounds | JAPAN TOBACCO INC. (JP) | 2008-12-11 | — | — | US | disclosed |
| US-20080064871-A1 | Production Method of Nitrogen-Containing Fused Ring Compounds | JAPAN TOBACCO INC. (JP) | 2008-03-13 | — | — | US | disclosed |
| US-20080064871-A1 | Production Method of Nitrogen-Containing Fused Ring Compounds | JAPAN TOBACCO INC. (JP) | 2008-03-13 | — | — | US | disclosed |
| US-20080064871-A1 | Production Method of Nitrogen-Containing Fused Ring Compounds | JAPAN TOBACCO INC. (JP) | 2008-03-13 | — | — | US | disclosed |
| EP-1820515-A1 | NITROGEN-CONTAINING FUSED RING COMPOUND AND USE THEREOF | Japan Tobacco, Inc. (JP) | 2007-08-22 | — | — | EP | disclosed |
| US-20070010670-A1 | Nitrogen-containing fused ring compounds and use thereof | JAPAN TOBACCO INC. (JP) | 2007-01-11 | — | — | US | disclosed |
| US-20070010670-A1 | Nitrogen-containing fused ring compounds and use thereof | JAPAN TOBACCO INC. (JP) | 2007-01-11 | — | — | US | disclosed |
| US-20070010670-A1 | Nitrogen-containing fused ring compounds and use thereof | JAPAN TOBACCO INC. (JP) | 2007-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080305169-A1 | Pharmaceutical Compositions Comprising Nitrogen-Containing Fused Ring Coumpounds | NOD1, NLRP3, SLC10A1 | SLC22A12 446/4885CYP2C9 57/4885ABCG2 18/4885 |
| US-20070010670-A1 | Nitrogen-containing fused ring compounds and use thereof | NUDT1, NOD1, SLC28A1 | SLC22A12 260/4885CYP2C9 1539/4885ABCG2 336/4885 |
| US-20080064871-A1 | Production Method of Nitrogen-Containing Fused Ring Compounds | NOD1, XDH, URB2 | SLC22A12 371/4885CYP2C9 813/4885ABCG2 344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.